Zentalis Pharmaceuticals Llc
$ 5.11
11.82%
17 Jul - close price
- Market Cap 363,762,000 USD
- Current Price $ 5.11
- High / Low $ 5.34 / 4.68
- Stock P/E N/A
- Book Value 2.57
- EPS -1.74
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.52 %
- 52 Week High 6.95
- 52 Week Low 1.21
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Analyst Target Price
$6.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-26 | 2025-11-10 | 2025-08-06 | 2025-05-14 | 2025-03-26 | 2024-11-12 | 2024-08-09 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-09 |
| Reported EPS | -0.5031 | -0.49 | -0.37 | -0.37 | -0.67 | -0.6138 | -0.56 | -1.24 | 0.14 | -0.93 | -0.79 | -1.85 |
| Estimated EPS | -0.4683 | -0.61 | -0.48 | -0.52 | -0.61 | -0.6817 | -0.87 | -0.83 | -0.74 | -0.92 | -0.94 | -1.02 |
| Surprise | -0.0348 | 0.12 | 0.11 | 0.15 | -0.06 | 0.0679 | 0.31 | -0.41 | 0.88 | -0.01 | 0.15 | -0.83 |
| Surprise Percentage | -7.4311% | 19.6721% | 22.9167% | 28.8462% | -9.8361% | 9.9604% | 35.6322% | -49.3976% | 118.9189% | -1.087% | 15.9574% | -81.3725% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.45 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZNTL
2026-07-19 12:40:25
Zentalis Pharmaceuticals Inc. (ZNTL) saw its stock jump by over 10% after Mizuho initiated coverage with an "Outperform" rating and an $8 price target, citing attractive risk-reward for its cancer drug azenosertib. The stock's surge was driven by expectations of key Phase 2 data and upcoming Phase 3 trial visibility. Despite being a cash-burning, development-stage biotech, Zentalis has a strong balance sheet supporting its ongoing pivotal programs, making it an event-driven catalyst play for traders.
2026-07-19 02:40:26
Mizuho Securities has initiated a "Buy" rating for Zentalis Pharmaceuticals (ZNTL) with an $8.00 price target, based on analyst Graig Suvannavejh's assessment. Suvannavejh, known for a 21.5% average return on recommended stocks, covers the Healthcare sector. The broader analyst consensus for Zentalis Pharmaceuticals is a "Moderate Buy" with an average price target of $6.40, while the company reported a GAAP net loss of $35.35 million for the quarter ending March 31.
2026-07-18 05:09:46
Mizuho has initiated coverage on Zentalis Pharmaceuticals with an "Outperform" rating. This rating suggests that Mizuho analysts expect Zentalis Pharmaceuticals stock to perform better than the broader market or its sector. The report, however, does not provide details on the specific reasons for this optimistic outlook.
2026-07-17 20:41:05
Zentalis Pharmaceuticals will present overall survival data from its DENALI Part 1b study of azenosertib at the European Society for Medical Oncology (ESMO) Congress 2026. This rapid oral presentation will highlight the long-term survival benefits of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer. Additionally, a trial-in-progress poster presentation will detail the ASPENOVA Phase 3 study of azenosertib monotherapy for the same patient population.
2026-07-17 20:41:05
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its investigational WEE1 inhibitor, azenosertib, will be featured in two presentations at the ESMO Congress 2026. A rapid oral session will share overall survival data from the Phase 2 DENALI study in platinum-resistant ovarian cancer (PROC), while a trial-in-progress poster will detail the Phase 3 ASPENOVA study. Both studies aim to support accelerated and full approval pathways for azenosertib as a biomarker-driven treatment for Cyclin E1-positive PROC.
2026-07-17 16:15:00
Zentalis Pharmaceuticals announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, highlighting overall survival data for azenosertib in platinum-resistant ovarian cancer from the DENALI Part 1b study with a rapid oral presentation. The company will also present a trial-in-progress poster for the ASPENOVA Phase 3 study, comparing azenosertib monotherapy to standard chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer. These presentations underscore Zentalis's focus on advancing azenosertib as a biomarker-driven treatment for this patient population.
